Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer

Published:2017-12-08 Issue:5 Volume:24 Page:1176-1189
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Chen Chun-Han,Changou Chun A.,Hsieh Tsung-Han,Lee Yu-Ching,Chu Cheng-Ying,Hsu Kai-Cheng,Wang Hao-Ching,Lin Yu-Chen,Lo Yan-Ni,Liu Yun-Ru,Liou Jing-Ping,Yen Yun

Funder

Ministry of Science and Technology of the Republic of China

Taipei Medical University

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

2. Recent advances of vacuolar protein-sorting 34 inhibitors targeting autophagy;Bioorganic Chemistry;2024-02

3. Evaluation of a spray-dried amorphous solid dispersion formulation of ID11916, a new molecular entity with dual inhibition mechanisms targeting the androgen receptor and phosphodiesterase type-5;Journal of Pharmaceutical Investigation;2023-12-28

4. Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells;Current Issues in Molecular Biology;2023-10-07

5. Pan-cancer Analysis of the Prognostic and Immunological Effects of PIK3C3;2023-09-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP